articleThe LancetOct 1, 2005Closed access

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

The Christie Hospital · Tata Memorial Hospital · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,088
total citations
FWCI
120.66
Percentile
100%
References
37
Citations per year

Authors

11

Topics & keywords

Keywords
  • Gefitinib
  • Medicine
  • Internal medicine
  • Placebo
  • Hazard ratio
  • Clinical endpoint
  • Lung cancer
  • Population
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding